Educate Why Aducanumab Isn't a Miracle for Alzheimer's

You'll hear controversy about aducanumab (Aduhelm), the first new med for Alzheimer's disease in almost 20 years.

It's a monoclonal antibody given as an IV infusion every 4 weeks.

Aducanumab is only approved for Alzheimer's patients with mild cognitive impairment or mild dementia. It's NOT for more severe disease or other types of dementia...there are no data in these patients.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals